BARD C R INC (BCR) Stock Price & Overview
NYSE:BCR • US0673831097
Current stock price
The current stock price of BCR is 331.24 null. Today BCR is down by -0.59%. In the past month the price decreased by -1.65%. In the past year, price increased by 47.44%.
BCR Key Statistics
- Market Cap
- 24.144B
- P/E
- 43.42
- Fwd P/E
- 25.52
- EPS (TTM)
- 7.63
- Dividend Yield
- 0.24%
BCR Stock Performance
BCR Stock Chart
BCR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BCR. When comparing the yearly performance of all stocks, BCR is one of the better performing stocks in the market, outperforming 85.44% of all stocks.
BCR Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BCR. While BCR belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
BCR Earnings
BCR Forecast & Estimates
BCR Financial Highlights
Over the last trailing twelve months BCR reported a non-GAAP Earnings per Share(EPS) of 7.6288. The EPS increased by 12.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.73% | ||
| ROA | 10.25% | ||
| ROE | 28.3% | ||
| Debt/Equity | 0.57 |
BCR Ownership
About BCR
Company Profile
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems etc.
Company Info
BARD C R INC
730 CENTRAL AVE
MURRAY HILL NJ 07974
CEO: Timothy M. Ring
Phone: 908-277-8000
BARD C R INC / BCR FAQ
What does BARD C R INC do?
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems etc.
What is the current price of BCR stock?
The current stock price of BCR is 331.24 null. The price decreased by -0.59% in the last trading session.
What is the dividend status of BARD C R INC?
BARD C R INC (BCR) has a dividend yield of 0.24%. The yearly dividend amount is currently 1.04.
What is the ChartMill rating of BARD C R INC stock?
BCR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is BARD C R INC (BCR) stock traded?
BCR stock is listed on the New York Stock Exchange exchange.